Biotech Values

[DewDiligence]

ENTA-related excerpts from C&EN NASH article:

In addition to sealing NASH’s fate as a hot therapeutic area, [ICPT’s] FLINT data helped make the farnesoid X nuclear receptor (FXR) the drug target du jour. In addition to Intercept’s obeticholic acid, FXR agonists from multiple companies—including Gilead, Novartis, and Enanta Pharmaceuticals—are already in early to mid-stage studies.

…The obvious areas to improve upon are the potency and selectivity of FXR agonists.

...For example, the latest compound to enter the clinic, Enanta’s EDP-305, is 20 times as potent as obeticholic acid. Enanta CEO Jay Luly says his company’s chemists have already come up with next-generation compounds that boast 10,000 times the binding affinity for FXR of the Intercept molecule.

Please see #msg-125454754 for related info.